Global Biodefense March 6, 2020
The Biomedical Advanced Research and Development Authority (BARDA) issued the BAA-18-100-SOL-00003-Amendment 13 to solicit proposals for advanced development and licensure of COVID-19 diagnostics, vaccines, or medicines such as therapeutics or antivirals. COVID-19 response related Areas of Interest includes: Diagnostic assay for human coronavirus using existing FDA-cleared platforms, Point-of-care diagnostic assay for detection of SARS-CoV-2 virus, Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection), COVID-19 Vaccine, COVID-19 Therapeutics, Immunomodulators or therapeutics targeting lung repair, Pre-exposure and post-exposure prophylaxis, Respiratory protective devices, Ventilators, Advanced Manufacturing Technologies. BARDA will only accept submissions related to the SARS-CoV-2 virus or the COVID-19 disease until further notice. Offers Due: Apr 30, 2020 04:30 pm EDT. The final full proposal submission deadline is October 31, 2020 or as specified in the invitation letter…read more. BAA